Efficacy and safety

Not actual patient

Same proven efficacy1-3
BAFIERTAM® (monomethyl fumarate) delayed-release capsules have the same efficacy as Tecfidera® (dimethyl fumarate) delayed-release capsules, which have been shown to:
Blue bar chart with magenta arrow pointing downward.
reduce the number of relapses
Blue outlined person with magenta clock.
delay the progression of disability
Outline of blue brain.
slow the development of brain lesions
No dietary restrictions
You can take BAFIERTAM with or without food, and there are no diet or alcohol restrictions.1
You do not need to count calories, restrict your diet, or change your eating and drinking habits with BAFIERTAM.1
This is because:
Magenta dash icon.
With BAFIERTAM, your body’s ability to absorb monomethyl fumarate (MMF) remains consistent after ingesting a high-fat, high-calorie meal.1,4
Magenta dash icon.
With Vumerity® (diroximel fumarate) delayed-release capsules, MMF absorption is reduced significantly when taken with alcohol or a high-fat, high-calorie meal.4,5
Fewer GI side effects than Tecfidera
BAFIERTAM is not metabolized in the digestive tract and does not produce methanol. It has been shown to have reduced incidence, severity, and duration of GI side effects compared to Tecfidera.6
If you are experiencing challenging gastrointestinal side effects with Tecfidera, BAFIERTAM may be a better-tolerated option, without having to switch to an alternative class of disease modifying therapy (DMT).6
Lower rate of lymphopenia

A study looked back at patients who had a fumarate medication switch and their development of lymphopenia,7 a known side effect of many DMTs in which patients’ lymphocyte counts drop below 1000 per microliter.8

The results showed that 56% of patients developed lymphopenia after switching from dimethyl fumarate (DMF) to Vumerity, compared to 0% of patients who switched to BAFIERTAM.7

If you are considering a medication switch from Tecfidera or generic DMF, BAFIERTAM may be the better option.7
Quick elimination

BAFIERTAM is quickly eliminated from the body, with the active metabolite generally undetectable within 24 hours under fasting conditions.1

This means BAFIERTAM does not remain in the body for long after treatment is stopped. If you have questions about managing side effects, treatment changes, or stopping treatment, speak with your healthcare team.

References

1. BAFIERTAM. Prescribing Information. Banner Life Sciences LLC.

2. Gold R, Kappos L, Arnold DL, et al. 2012. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 367(12):1098-1107. doi:10.1056/NEJMoa1114287.

3. Fox RJ, Miller DH, Phillips JT, et al. 2012. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 367(12):1087-1097. doi:10.1056/NEJMoa1206328.

4. VUMERITY. Prescribing Information. Biogen Inc.

5. CDER US FDA. Clinical pharmacology and biopharmaceutics review(s). Application Number 211855Orig1s000. Rev_211855(2)_package_Redacted. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211855Orig1s000ClinPharmR.pdf. [Accessed: July 9 2025].

6. Wynn, D., Lategan, T. W., Sprague, T. N., Rousseau, F. S., & Fox, E. J. (2020). Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate. Multiple sclerosis and related disorders, 45, 102335. https://doi.org/10.1016/j.msard.2020.102335.

7. Banks, A., et al. 2026. Retrospective review of lymphocyte changes when switching between fumarates in patients with multiple sclerosis. Mult Scler Relat Disord., 107, 106968. doi:10.1016/j.msard.2026.106968.

8. Fischer, S., Proschmann, U., Akgün, K., & Ziemssen, T. 2021. Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects. Cells, 10(11), 3177. doi:10.3390/cells10113177.

Tecfidera® and Vumerity® are registered trademarks of Biogen Inc.

Indication and Important Safety Information
Indication and Important Safety Information
Indications

BAFIERTAM® (monomethyl fumarate) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is not known if BAFIERTAM is safe and effective in children.

Important Safety Information

  • Do not take BAFIERTAM if you have had an allergic reaction (such as welts, hives, swelling of the face, lips, mouth or tongue, or difficulty breathing) to monomethyl fumarate, dimethyl fumarate, diroximel fumarate, or any of the ingredients in BAFIERTAM.
  • Do not take BAFIERTAM if you are taking dimethyl fumarate or diroximel fumarate.

Before taking and while you take BAFIERTAM, tell your Healthcare Provider about all your medical conditions, including if you:

  • have liver problems.
  • have or have had low white blood cell counts or an infection.
  • are pregnant or plan to become pregnant. It is not known if BAFIERTAM will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if BAFIERTAM passes into breast milk. Talk to your healthcare provider about the best way to feed your baby while using BAFIERTAM.

Tell your Healthcare Provider about all other medicines you take including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Serious Adverse Reactions:

BAFIERTAM may cause serious side effects, including:

Allergic reactions (such as welts, hives, swelling of the face, lips, mouth or tongue, or difficulty breathing). Stop taking BAFIERTAM and get emergency medical help right away if you get any of these symptoms.

PML (progressive multifocal leukoencephalopathy) a rare brain infection that usually leads to death or severe disability over a period of weeks or months. Contact your Healthcare provider right away if you if you notice new or worsening symptoms such as weakness on one side of the body, vision problems, trouble thinking, or changes in memory or personality. Your healthcare provider may stop BAFIERTAM if PML is suspected. Increased risk of serious infections, including shingles (herpes zoster) and central nervous system infections.

Decrease in your white blood cell count Your healthcare provider will do a blood test to check your white blood cell count before you start treatment with BAFIERTAM and while you are on therapy. You should have blood tests after 6 months of treatment and every 6 to 12 months after that.

Liver problems. BAFIERTAM may cause serious liver problems that may lead to liver failure, a liver transplant, or death. Blood tests will be done before and during treatment to check your liver. Tell your healthcare provider right away if you have symptoms such as unusual tiredness, loss of appetite, dark urine, yellowing of your skin or eyes, or stomach pain. BAFIERTAM may be stopped if liver injury is suspected.

Flushing: BAFIERTAM may cause flushing, which can feel like warmth, redness, itching, or a burning sensation, usually on the face or upper body. Flushing often starts soon after beginning treatment and usually improves or goes away over time. Most flushing reactions are mild to moderate, but some people have stopped treatment because of flushing.

Tell your healthcare provider if flushing is bothersome or does not improve.

Serious Stomach and Intestinal Problems: Serious stomach and intestinal problems have been reported with medicines like BAFIERTAM. These problems can include severe stomach pain, ulcers, bleeding, blockage, or tears in the stomach or intestines, and in rare cases can be fatal. Serious stomach problems have occurred most often within the first 6 months of treatment.

Call your healthcare provider right away if you have new or worsening severe stomach pain, vomiting, blood in your stool, black stools, or other severe stomach symptoms. Your healthcare provider may stop BAFIERTAM if serious stomach problems occur.

Common Adverse Reactions:

The most common side effects of BAFIERTAM include:

  • Flushing, which may feel like warmth, redness, itching, or a burning sensation.
  • Stomach‑related problems, such as nausea, vomiting, diarrhea, stomach pain, and indigestion.
  • Skin reactions, including rash or itching.

These side effects were most common early in treatment and often became less frequent over time.

Other side effects reported after the medicine became available include hair thinning or hair loss. These are not all the possible side effects of BAFIERTAM. Call your healthcare provider for medical advice about side effects.

For more detailed information, please refer to the full Prescribing Information here.

To report SUSPECTED ADVERSE REACTIONS, contact Banner Life Sciences toll free at phone: 1-866-MMF-95MG, or the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch.

Dark and mid blue shape divider.
BAFIERTAM logo.
Contact Us

www.cyclepharma.com

www.cyclevita.life

#CycleVitaUSA

#CycleVitaUSA

@cycle-pharmaceuticals

BAFIERTAM® is a registered trademark of Banner Life Sciences, LLC, a Cycle Pharmaceuticals company.
Cycle Vita™ is a trademark of Cycle Pharmaceuticals Limited in the United States.

© 2026 Cycle Pharmaceuticals Limited. All rights reserved.

Compliance & PoliciesAccessibility StatementModern Slavery Statement

US-MMF-2600137 | July 2026